Serum level adjusted dosage of once-daily aminoglycoside therapy in critically III patients: Results of a prospective study;Serumspiegelorientierte dosierung der einmal taglichen aminoglykosidtherapie beim kritisch kranken: Ergebnisse einer prospektiven untersuchung

Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie

Volumn 34, Issue 5, 1999, Pages 288-295

  Reimann, Ilselore ^a   Meier Hellmann, A ^a   Pfeifer, R ^a   Traut, T ^a   Schilling, A ^a   Stein, C ^a   Reinhart, K ^a   Hoffmann, A ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Aminoglycosides; Critically ill patient; Drug monitoring; Once daily dosage

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CREATININE; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANALYTIC METHOD; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICAL ILLNESS; DISTRIBUTION VOLUME; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; ANTIBIOTIC PROPHYLAXIS; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; INTENSIVE CARE; METABOLIC CLEARANCE RATE; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; URINE;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CREATININE; CRITICAL ILLNESS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMANS; INTENSIVE CARE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROSPECTIVE STUDIES; TOBRAMYCIN;

EID: 0032588391     PISSN: 09392661     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-1999-186     Document Type: Article

References (41)

1. Moore RD, Lietman PS, Smith CR: Clinical response to amino-glycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 1987; 155: 93-99
2. Cipolle RJ, Seiffert RD, Zaske DE, Strate RG: Systematically individualizing tobramycin dosage regimens. J. Clin. Pharmacol. 1980; 0: 570-580
3. Thomas L, WaIb D: Niere und Harnwege. In: Labor und Diagnose. Thomas L, 4. Aufl., Die Med. Verl.-Ges., Marburg 1992
4. Möller D: Pharmacokinetic system: computer aided dosing regimens with a new software package. Int. J. Clin. Pharm. Th. 1992; 30: 501-502
5. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
6. Thomas L, Walb D: Niere und Harnwege. In: Labor und Diagnose. Thomas L, 4. Aufl., Die Med. Verl.-Ges., Marburg 1992
7. ABBOTTBASE® Pharmacokinetic Systems Operations Manual
8. Thomann P: Methods manual non-compartmental analysis. In: TopFit: Version 2.0. Pharmacokinetic and pharmacodynamic data analysis system for the PC. Heinzel G, Woloszczak R, Thomann P. Gustav Fischer, Stuttgart 1993
9. Hüsler J, Zimmermann H: Statistische Prinzipien für medizinische Projekte. Hans Huber, Bern 1993
10. SPSS® für windowsTM, Anwenderhandbuch 1993
11. Ioannides-Demos LL, Li SC, Bastone EB, Spelman DW, Hooper RE, Cousins VC, McLean AJ: Absence of toxicity in patients with malignant otitis externa following long-term treatment with high dosage tobramycin. J. Antimicrob. Chemoth. 1994; 34: 267-274
12. Karlowsky JA, Zhanel GG, Davidson RJ, Hovan DJ: Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa. Antimicrob. Agents Ch. 1994; 38: 1165-1168
13. Rodvold KA, Pryka RD, Kuehl PG, Blum RA, Donahue P: Bayesian forecasting of serum gentamicin concentrations in intensive care patients. Clin. Pharmacokinet. 1990; 18: 409-418
14. Marik PE: Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth. Intens. Care 1993; 21: 172-173
15. MacGowan A, Reeves D: Serum aminoglycoside concentrations: the case for routine monitoring. J. Antimicrob. Chemother. 1994; 34: 829-837
16. Cronberg S: Simplified monitoring of aminoglycosides. J. Anti-microb. Chemother. 1994; 34: 819-827
17. Anaizi N: Once-daily dosing of aminoglycosides. Int. J. Clin. Pharmacol. Ther. 1997; 35: 223-226
18. Fachinformation Gernebcin® 1996
19. Fachinformation Certomycin® 1996
20. Fachinformation Refobacin® 1996
21. Blaser J: Aminoglykoside einmal täglich dosieren. Schweiz. Med. Wochenschr. 1996; 126 (Suppl. 76): 39S-48S
22. Zimmerli W, Lew DP: Use of aminoglycosides: the Swiss consensus. Schweiz. Med. Wochenschr. 1996; 126 (Suppl. 76): 5S-8S
23. Bertino JS, Rodvold KA, Destache CJ: Cost considerations in therapeutic drug monitoring of aminoglycosides. Clin. Pharmacokinet. 1994; 26: 71-81
24. Blaser J: Aminoglykoside einmal täglich dosieren. Schweiz. Med. Wochenschr. 1996; 126 (Suppl. 76): 39S-48S
25. Anaizi N: Once-daily dosing of aminoglycosides. Int. J. Clin. Pharmacol. Ther. 1997; 35: 223-226
26. Dehne MG, Sablotzky A, Kuntzsch U, Papke G, Benson M, Hempelmann G: Der Einfluß der Aminoglykosidtherapie auf die Nierenfunktion bei operativen Intensivpatienten. Intensiv- und Notfallbehandlung. 1996; 21: 80-86
27. Ioannides-Demos LL, Li SC, Bastone EB, Spelman DW, Hooper RE, Cousins VC, McLean AJ: Absence of toxicity in patients with malignant otitis externa following long-term treatment with high dosage tobramycin. J. Antimicrob. Chemoth. 1994; 34: 267-274
28. Blaser J: Aminoglykoside einmal täglich dosieren. Schweiz. Med. Wochenschr. 1996; 126 (Suppl. 76): 39S-48S
29. Prins JM, Büller HR, Kuijper EJ, Tange RA, Speelman P: Once-daily gentamicin versus once-daily netilmicin in patients with serious infections - a randomized clinical trial. J. Antimicrob. Chemother. 1994; 33: 823-835
30. Moore RD, Lietman PS, Smith CR: Clinical response to amino-glycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 1987; 155: 93-99
31. Blaser J, Stone BB, Groner MC, Zinner SH: Impact of netilmicin regimens on the activity of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 1985; 28: 64-68
32. Bernard PA, Péchère JC, Hébert B: Altered objective audiometry in aminoglycosides-treated human neonates. Arch. Otorhinolaryngol. 1980; 228: 205-210
33. Zenner HP, Schacht J: Hörverlust durch Aminoglykosidantibiotika: Angriff am Membranbaustein PIP2 in äußeren Haarzellen als Wirkmechanismus. HNO 1986; 34: 417-423
34. Prins JM, Büller HR, Kuijper EJ, Tange RA, Soeekman P: Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341: 335-339
35. Pettorossi VE, Ferraresi A, Errico P, Draicchio F, Dionisotti S: The impact of different dosis regimens of the aminoglycosides netilmicin and amikacin on vestibulotoxicity in the guinea pig. Arch. Otorhinolarygol. 1990; 247: 277-282
36. Blaser J: Aminoglykoside einmal täglich dosieren. Schweiz. Med. Wochenschr. 1996; 126 (Suppl. 76): 39S-48S
37. Böttger HC, Oellerich M, Sybrecht GW: Use of aminoglycosides in critically ill patients: individualization of dosage using Bayesian statistics and pharmacokinetic principles. Ther. Drug Monit. 1988; 10: 280-286
38. Heinze V: Erhöhtes Serumkreatinin - richtige Bewertung. In: Nieren- und Hochdruckkrankheiten. Kühn K, Baldamus CA, Uhlich E, Stein G (Hrsg), Wolfgang Pabst, Lengerich 1993
39. Moore RD, Lietman PS, Smith CR: Clinical response to amino-glycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 1987; 155: 93-99
40. Karlowsky JA, Zhanel GG, Davidson RJ, Hoban DJ: Postantibiotic effect in Pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro. J. Antimicrob. Chemother. 1994; 33: 937-947
41. Fachinformation Certomycin® 1996